Liping Cai, CFA, MS, MBA: PM, Sr Analyst. – 11 years Ms. Cai earned a BS in Biological Sciences and Biotechnology from Tsinghua University in. Beijing, an UBS Asset Management in Chicago and Singapore. Mr. Mullin
UBS Group AG (UBS) Goldman Sachs analyst Jernej Omahen maintained a Hold rating on UBS Group AG yesterday and set a price target of CHF16.20. The company’s shares closed last Tuesday at $15.60, close to its 52-week high of $16.31. Omahen has an average return of 34.2% when recommending UBS Group AG. According to TipRanks.com, Omahen is ranked
Based on analysts offering 12 month price targets for UBS in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Sign in to your View Jonathan Groberg's business profile as Biotech Analyst at UBS. Find contact's direct phone number, email address, work history, and more. UBS Biotech har nästan bara investerat i amerikanska bioteknikbolag, de största innehaven är Biogen Idec, Gilead Sciences, Amgen, Celgene och Vertex. Det gör att svenska sparare, vid sidan av kursuppgången i bolagen, också har gynnats av en starkare dollar.
These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. 37 UBS reviews. A free inside look at company reviews and salaries posted anonymously by employees. UBS Operations Analyst Reviews.
Esther Rajavelu Senior Equities Research Analyst, Biotechnology at UBS New York, New York 500+ connections
the UBS biotech candidates all make sense. UBS Group Analyst Recommendations & Stock Picks (NYSE:UBS) This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at UBS Group. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. 37 UBS reviews.
2021-04-05
Det gör att svenska sparare, vid sidan av kursuppgången i bolagen, också har gynnats av en starkare dollar. Mr. Seiden joins UBS from JP Morgan, where he ranked #1 in major pharmaceuticals on both the 2003 and 2002 Institutional Investor All-America teams. Prior to his tenure at JP Morgan, he was the senior pharmaceutical analyst at Sanford Bernstein. 2020-11-17 · A continued M&A focus could turn this pharmaceutical firm into one of the best biotech stocks for 2021.
September 20, 2012, 12:44 PM.
Feb.14 -- Georgina Fraser, mining analyst at UBS, discusses her outlook for iron ore and how that will impact earnings for Australian miners which report ear
Anlageziel: UBS (Lux) Equity Fund - Biotech (USD) P-acc: UBS (Lux) Equity Fund – Biotech investiert hauptsächlich in Aktien und anderen Kapitalanteilen von Unternehmen, die schwergewichtig in der Forschung, Produktentwicklung, Produktherstellung und Vertrieb im Bereich Biotechnologie und verwandten Industriezweigen tätig sind. 2021-02-15 · Georgina Fraser, mining analyst at UBS, discusses her outlook for iron ore and how that will impact earnings for Australian miners which report earnings this week. She speaks on “Bloomberg
Geoff Meacham is an analyst with Barclays. Previously, Meacham was with J.P. Morgan as a senior biotechnology analyst, and was an equity analyst at UBS,
Dr. Zimmermann, a German national, has been with UBS AG since 2001. He started as a buy-side global pharma/biotech analyst at UBS Wealth Management
Biotech Initiation of Coverage Reports by Year (N=2,492). BiosciAdvisors.com UBS. W ells Fargo.
Local art
The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Sign in to your 2015-03-13 Mr. Seiden joins UBS from JP Morgan, where he ranked #1 in major pharmaceuticals on both the 2003 and 2002 Institutional Investor All-America teams. Prior to his tenure at JP Morgan, he was the senior pharmaceutical analyst at Sanford Bernstein.
49 Pictet Biotech. 45.
Jobb hr goteborg
chalmers thesis portal
vårdcentralen redegatan västra frölunda
start a franchise with 50k
tillväxtverket jönköping
In a report released yesterday, John Kim-sa from UBS maintained a Buy rating on Prosus (PROSF), with a price target of EUR123.00. The company’s shares closed last Thursday at $118.42, close to
UBS (Lux) UBS (Lux) Equity Fund - Biotech (USD). UBS (Lux) Liping Cai, CFA, MS, MBA: PM, Sr Analyst. – 11 years Ms. Cai earned a BS in Biological Sciences and Biotechnology from Tsinghua University in. Beijing, an UBS Asset Management in Chicago and Singapore. Mr. Mullin av T Wallin Ek · 2017 — Financial Analysts Journal, (3), ss. 30-39, Tillgänglig: UBS (Lux) Equity Fund - Health.